The Technology, Exercise Programming, and Activity Prescription for Enhanced Mobility (TEAM) Study

Sponsor
Western University, Canada (Other)
Overall Status
Recruiting
CT.gov ID
NCT04544904
Collaborator
(none)
192
1
3
18.4
10.4

Study Details

Study Description

Brief Summary

Many individuals with osteoarthritis (OA) (up to 45%) are referred to an orthopaedic surgeon for a joint replacement prematurely or will not be candidates for surgery. These individuals need appropriate (non-operative) care to help reduce their pain and enhance their mobility. We are studying the use of innovative technology to help physicians give physical activity advice for patients to become more active and provide free online resources to help patients understand OA self-management and exercise, especially when they have barriers to accessing formal care. Individuals with OA that are referred to a specialized clinic will receive one of three interventions: usual care (handout on resources), a physical activity prescription by a doctor, or the prescription and a link to a free web-based platform (website) on non-operative management of OA with patient education and exercise videos. Our goal is to help with non-operative management strategies to improve quality of life, reduce pain, improve mobility, and possibly delay or prevent a joint replacement.

Osteoarthritis is a condition where people feel joint pain or stiffness. Joints are the body parts where two bones join together with softer material (cartilage) between them. In osteoarthritis, this cartilage wears down. It is the biggest cause for disability worldwide. Helping people with osteoarthritis starts with education, physical activity, and physiotherapy. Doctors can also prescribe braces, injections or medications. For severe osteoarthritis when nothing else helps, surgery can be done to replace the joint.

Doctors often refer patients for surgery too soon. Skipping steps of care may mean unnecessary surgery and longer wait times. The Musculoskeletal Rapid Access Clinic (now called Clinic) in London was set up to solve these problems. They screen patients before referring them to a surgeon, and do not refer almost half of patients. Our goal is to support these patients with new ways to make their non-surgical treatment better.

The first way is through physical activity 'prescription'. It works well for other chronic conditions and patients say it helps. We don't know how well it works for people with osteoarthritis. Most doctors have little time, training or experience for prescribing physical activity. Technology can make it easier for doctors and patients. We have designed a tool to help doctors prescribe physical activity and a smartphone app to track patient activity. We have also created a free website. This includes patient education, exercise videos, and virtual physiotherapy. This can be important for individuals who can't access in-person care.

Condition or Disease Intervention/Treatment Phase
  • Device: PAARx
  • Device: JM
N/A

Detailed Description

Osteoarthritis (OA) is the leading cause of disability worldwide and affects more than 4.4 million Canadians. Current evidence-based guidelines for OA management recommend weight management, patient education, physical activity, physiotherapy (PT), bracing, viscosupplementation, and anti-inflammatory/pain medications prior to joint replacement surgery. Unfortunately, current practice trends are not consistent with these guidelines, as nearly half of patients with OA referred to orthopedic surgeons do not require total joint arthroplasty (TJA) at the time of initial consultation. Through the Southwest Musculoskeletal Rapid Access Clinic (RAC), approximately ten referrals (20%) are rejected each day due to OA criteria not met, and a further 20% are assessed as non-operative.

We aim to identify individuals with 'mild to moderate' OA and optimize their first-line non-operative management, starting with physical activity and education.

Physical activity prescriptions are effective in increasing patient levels of physical activity, and 93% of patients surveyed want advice on physical activity from their physicians; but it is underused.

Physicians cite lack of time and inadequate training as barriers. Electronic screening of physical activity behaviours can save time for physicians, and the use of digital health tools can improve physical activity levels.

Patient education and physiotherapist-led group exercise therapy programs have shown to delay progression of knee OA symptoms and improve pain and function; however, two of the most significant barriers to accessing exercise programming is the cost (~approximate $425-475 per 6-8-week session) and accessibility to attend the exercise session (proximity to facility, remote/rural communities, etc.).

The Need for a Solution that targets both Providers and Patients Screening for baseline physical activity levels and including educational components significantly increase intervention effectiveness.

We have previously tested the feasibility of implementing an e-health tool to support physical activity counselling by physicians during patients' periodic health review. We will adapt and implement this tool, Physical Activity and App Prescription (PARx) to screen and provide tailored resources for physical activity in the setting of OA. We will use tablet computers and email, directly linked with the electronic medical record (EMR), to engage patients in contemplating their own physical activity levels, start conversations with their healthcare providers (in this case, primary care physicians with additional training in sport and exercise medicine), and support customized, patient-centered health care. After patients enter their information, they will receive evidence-based behavioural change supports to help them meet their goals.

The automated algorithm assesses current activity level, risk factors/comorbidities and readiness for change. Based on the answers provided, patients are risk-stratified and tailored resources will be provided to the patient and to their clinician in the form of decision support tools embedded in the EMR. This will include the novel implementation of an exercise tracking platform via the smartphone app (myrecovery.ai).

The web-based platform Joint Management (JM) is a free, readily accessible evidenced-based resource focusing on non-operative management strategies for mild to moderate hip and knee OA. The platform will include exercise programming (videos, pictures, and descriptions of the exercises) and patient education (benefits of exercise, lifestyle modifications, nutrition, injections, etc.), to assist the patient engage in self-management. JM will also include the option for (paid) virtual access to PTs, who can provide individualized support, recommendations and exercise programming via the platform.

RATIONALE:

Creating customized physical activity plans with automated reminders and other supports addresses the problem of self-efficacy in providers by developing an evidence-based automated method, while also addressing the issue of patient adherence by using tailored behaviour change techniques, through assessing readiness for change, and helping patients create new habits.

The motivation for JM is to create a free, online evidence-based OA education and exercise programming resource for those that are not able to afford or access community-based exercise programs. The virtual PT option will help optimize patient's experience with the web-based platform, offering support and personalized recommendations regarding management of their condition and exercise programming tailored to their specific abilities, preferences, and needs.

Why this is Innovative:

The evidence for using patient-reported measures and functional outcomes to guide quality improvement for personalized OA care in a systematic manner is in an early stage, meaning that this project can not only impact healthcare delivery and translate new knowledge into medical practice but help position Western University as a leader in this area. The novel technologies (PARx and JM) are innovative tools informed by patient priorities and co-designed with our patient partners, specifically geared towards 1) developing new and more personalized treatment approaches, 2) developing more effective self-management tools, and 3) reducing disparities in vulnerable and hard-to-reach populations. To this end, we will share our findings broadly with our patient partners and reach out to these harder-to-reach groups in particular.

EXPECTED OUTCOMES:

Health Outcomes: We expect to increase patients' physical activity and improve outcomes for individuals with mild to moderate OA. We aim to optimize non-operative management of OA symptoms and therefore possibly delay and/or prevent the need for TJA.

Academic Outcomes: We expect to develop a model of physical activity prescription and patient education that can be scaled up for implementation in primary care.

Societal Outcomes: Both novel technologies have the potential to be implemented across Canada, targeting modifying disease progression and, ideally, delaying or preventing TJA.

Innovative Technology 1: Physical Activity (PA) and App Prescription (Rx) (PARx) Physical Activity and App Prescription (PARx): Tablet/email software (REDCap) is used to collect physical activity data from patient input and prompt intervention by providers. The automated algorithm assesses current activity level, risk factors/comorbidities and readiness for change. Based upon their answers, patients will be risk-stratified and tailored resources will be provided to them in the form of a personalized prescription and free smartphone app (myrecovery.ai) to track activity levels.

Innovative Technology 2: Joint Management (JM) Joint Management (JM): This is a free online evidence-based OA education and exercise programming resource for those that are not able to afford or access community-based exercise programs, with a virtual physiotherapy (PT) option to offer support and personalized recommendations.

OBJECTIVES:

The objective of the proposed study is to 1) determine if PARx and JM will improve pain, increase physical activity levels, and improve functional outcomes in patients with mild to moderate hip or knee OA

RESEARCH QUESTIONS:
  1. Does the use of novel technology (PARx) affect patient reported outcomes in individuals with mild to moderate hip or knee OA?

  2. Does PARx influence activity levels in individuals with mild to moderate hip or knee OA?

  3. Does the use of novel technology (PARx and JM) affect patient reported and functional outcomes in individuals with mild to moderate hip or knee OA?

  4. What are the experiences and perceptions of patients and physicians during this process?

SPECIFIC AIMS:

Measure and compare A1) patient reported outcomes (pain, joint stiffness, disability, quality of life, disease knowledge, self-efficacy, depression, and fatigue), A2) physical activity levels, and A3) functional outcomes with those that have access (PARx and JM) and those that do not have access (usual care) to the technology. Determine A4) participant and physician experiences.

HYPOTHESES:

We hypothesize that access to technology-facilitated physical activity prescription (PARx) and access to the web-based platform (JM) will H1) improve patient reported outcomes (pain, joint stiffness, disability, quality of life, disease knowledge, self-efficacy, depression, and fatigue), H2) increase PA levels, and H3) improve functional outcomes in individuals with mild to moderate hip or knee OA compared to usual care. We hypothesize that access to JM will result in a greater improvement than PARx alone.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
192 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Novel Uses of Technology for Individuals With Mild to Moderate Hip or Knee Osteoarthritis: The Technology, Exercise Programming, and Activity Prescription for Enhanced Mobility (TEAM) Study
Actual Study Start Date :
Jun 18, 2021
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Usual Care

Patients will receive the usual care.

Experimental: PAARx

Patients will be prescribed technology-based physical activity programming.

Device: PAARx
Prescription Physical Activity Programming Application

Experimental: PAARx and JM

Patients will be prescribed technology-based physical activity programming and be referred to a web-based resource for evidence-based joint management.

Device: PAARx
Prescription Physical Activity Programming Application

Device: JM
Joint Management (JM) web-based joint management resource.

Outcome Measures

Primary Outcome Measures

  1. height [Baseline]

    height in cm

  2. height [2 months]

    height in cm

  3. height [6 months]

    height in cm

  4. height [12 months]

    height in cm

  5. body mass index (derived) [Baseline]

    body mass index as calculated with height and weight

  6. body mass index (derived) [2 months]

    body mass index as calculated with height and weight

  7. body mass index (derived) [6 months]

    body mass index as calculated with height and weight

  8. body mass index (derived) [12 months]

    body mass index as calculated with height and weight

  9. abdominal circumference [Baseline]

    abdominal circumference in cm

  10. abdominal circumference [2 months]

    abdominal circumference in cm

  11. abdominal circumference [6 months]

    abdominal circumference in cm

  12. abdominal circumference [12 months]

    abdominal circumference in cm

  13. weight [Baseline]

    weight kg , weight, body mass index (derived), abdominal circumference, and medical history to assess for comorbid disease.

  14. weight [2 months]

    weight kg , weight, body mass index (derived), abdominal circumference, and medical history to assess for comorbid disease.

  15. weight [6 months]

    weight kg , weight, body mass index (derived), abdominal circumference, and medical history to assess for comorbid disease.

  16. weight [12 months]

    weight kg , weight, body mass index (derived), abdominal circumference, and medical history to assess for comorbid disease.

  17. PA Evaluation [Baseline]

    PA levels will be measured as a composite measure using smartphone app/accelerometer data (myrecovery.ai; steps per day, light/moderate/vigorous activity, and total MET-min) via the International PA Questionnaire - Short Form (IPAQ-SF) [15].

  18. PA Evaluation [2 months]

    PA levels will be measured as a composite measure using smartphone app/accelerometer data (myrecovery.ai; steps per day, light/moderate/vigorous activity, and total MET-min) via the International PA Questionnaire - Short Form (IPAQ-SF) [15].

  19. PA Evaluation [6 months]

    PA levels will be measured as a composite measure using smartphone app/accelerometer data (myrecovery.ai; steps per day, light/moderate/vigorous activity, and total MET-min) via the International PA Questionnaire - Short Form (IPAQ-SF) [15].

  20. PA Evaluation [12 months]

    PA levels will be measured as a composite measure using smartphone app/accelerometer data (myrecovery.ai; steps per day, light/moderate/vigorous activity, and total MET-min) via the International PA Questionnaire - Short Form (IPAQ-SF) [15].

  21. Functional Assessment 30 second sit-to-stand test [Baseline]

    30 second sit-to-stand test

  22. Functional Assessment 30 second sit-to-stand test [2 months]

    30 second sit-to-stand test

  23. Functional Assessment 30 second sit-to-stand test [6 months]

    30 second sit-to-stand test

  24. Functional Assessment 30 second sit-to-stand test [12 months]

    30 second sit-to-stand test

  25. Functional Assessment 40-meter fast-paced walk test [Baseline]

    40-meter fast-paced walk test

  26. Functional Assessment 40-meter fast-paced walk test [2 months]

    40-meter fast-paced walk test

  27. Functional Assessment 40-meter fast-paced walk test [6 months]

    40-meter fast-paced walk test

  28. Functional Assessment 40-meter fast-paced walk test [12 months]

    40-meter fast-paced walk test

  29. Hip Disability and OA Outcome Score (HOOS) [Baseline]

    Hip Disability and Osteoarthritis Outcome Score (HOOS) assesses patient pain (10 items), satisfaction including stiffness and range of motion (5 items), activity limitations-daily living (17 items), sports and recreation function (4 items), and hip related quality of life (4 items). Scores range from 0 to 100 with a score of 0 indicating the worst possible hip symptoms and 100 indicating no hip symptoms. This is a patient reported joint-specific score, which may be useful for assessing changes in hip pathology over time, with or without treatment.

  30. Hip Disability and OA Outcome Score (HOOS) [2 months]

    Hip Disability and Osteoarthritis Outcome Score (HOOS) assesses patient pain (10 items), satisfaction including stiffness and range of motion (5 items), activity limitations-daily living (17 items), sports and recreation function (4 items), and hip related quality of life (4 items). Scores range from 0 to 100 with a score of 0 indicating the worst possible hip symptoms and 100 indicating no hip symptoms. This is a patient reported joint-specific score, which may be useful for assessing changes in hip pathology over time, with or without treatment.

  31. Hip Disability and OA Outcome Score (HOOS) [6 months]

    Hip Disability and Osteoarthritis Outcome Score (HOOS) assesses patient pain (10 items), satisfaction including stiffness and range of motion (5 items), activity limitations-daily living (17 items), sports and recreation function (4 items), and hip related quality of life (4 items). Scores range from 0 to 100 with a score of 0 indicating the worst possible hip symptoms and 100 indicating no hip symptoms. This is a patient reported joint-specific score, which may be useful for assessing changes in hip pathology over time, with or without treatment.

  32. Hip Disability and OA Outcome Score (HOOS) [12 months]

    Hip Disability and Osteoarthritis Outcome Score (HOOS) assesses patient pain (10 items), satisfaction including stiffness and range of motion (5 items), activity limitations-daily living (17 items), sports and recreation function (4 items), and hip related quality of life (4 items). Scores range from 0 to 100 with a score of 0 indicating the worst possible hip symptoms and 100 indicating no hip symptoms. This is a patient reported joint-specific score, which may be useful for assessing changes in hip pathology over time, with or without treatment.

  33. Knee OA Outcome Score (KOOS) [Baseline]

    Knee injury and Osteoarthritis Outcome Score (KOOS) assesses patient pain (9 items), other symptoms (7 items), function in daily living (17 items), function in sport and recreation (5 items), and knee related quality of life (4 items). Scores range from 0 to 100 with a score of 0 indicating the worst possible knee symptoms and 100 indicating no knee symptoms. The KOOS is a patient reported joint-specific score, which may be useful for assessing changes in knee pathology over time, with or without treatment.

  34. Knee OA Outcome Score (KOOS) [2 months]

    Knee injury and Osteoarthritis Outcome Score (KOOS) assesses patient pain (9 items), other symptoms (7 items), function in daily living (17 items), function in sport and recreation (5 items), and knee related quality of life (4 items). Scores range from 0 to 100 with a score of 0 indicating the worst possible knee symptoms and 100 indicating no knee symptoms. The KOOS is a patient reported joint-specific score, which may be useful for assessing changes in knee pathology over time, with or without treatment.

  35. Knee OA Outcome Score (KOOS) [6 months]

    Knee injury and Osteoarthritis Outcome Score (KOOS) assesses patient pain (9 items), other symptoms (7 items), function in daily living (17 items), function in sport and recreation (5 items), and knee related quality of life (4 items). Scores range from 0 to 100 with a score of 0 indicating the worst possible knee symptoms and 100 indicating no knee symptoms. The KOOS is a patient reported joint-specific score, which may be useful for assessing changes in knee pathology over time, with or without treatment.

  36. Knee OA Outcome Score (KOOS) [12 months]

    Knee injury and Osteoarthritis Outcome Score (KOOS) assesses patient pain (9 items), other symptoms (7 items), function in daily living (17 items), function in sport and recreation (5 items), and knee related quality of life (4 items). Scores range from 0 to 100 with a score of 0 indicating the worst possible knee symptoms and 100 indicating no knee symptoms. The KOOS is a patient reported joint-specific score, which may be useful for assessing changes in knee pathology over time, with or without treatment.

  37. Intermittent and Constant OA Pain (ICOAP) [Baseline]

    This 11-item tool is designed to assess pain in individuals with hip or knee osteoarthritis taking into account both constant and intermittent pain experiences. There are two versions of this tool; one to assess pain in the knee joint and another assessing pain in the hip joint.

  38. Intermittent and Constant OA Pain (ICOAP) [2 months]

    This 11-item tool is designed to assess pain in individuals with hip or knee osteoarthritis taking into account both constant and intermittent pain experiences. There are two versions of this tool; one to assess pain in the knee joint and another assessing pain in the hip joint.

  39. Intermittent and Constant OA Pain (ICOAP) [6 months]

    This 11-item tool is designed to assess pain in individuals with hip or knee osteoarthritis taking into account both constant and intermittent pain experiences. There are two versions of this tool; one to assess pain in the knee joint and another assessing pain in the hip joint.

  40. Intermittent and Constant OA Pain (ICOAP) [12 months]

    This 11-item tool is designed to assess pain in individuals with hip or knee osteoarthritis taking into account both constant and intermittent pain experiences. There are two versions of this tool; one to assess pain in the knee joint and another assessing pain in the hip joint.

  41. Patient Global Assessment of Health Status (PGA) [Baseline]

    Patient global assessment (PGA) is one of the most widely used PROs in RA practice and research and is included in several composite scores such as the 28-joint Disease Activity Score (DAS28). PGA is often assessed by a single question with a 0-10 or 0-100 response.

  42. Patient Global Assessment of Health Status (PGA) [2 months]

    Patient global assessment (PGA) is one of the most widely used PROs in RA practice and research and is included in several composite scores such as the 28-joint Disease Activity Score (DAS28). PGA is often assessed by a single question with a 0-10 or 0-100 response.

  43. Patient Global Assessment of Health Status (PGA) [6 months]

    Patient global assessment (PGA) is one of the most widely used PROs in RA practice and research and is included in several composite scores such as the 28-joint Disease Activity Score (DAS28). PGA is often assessed by a single question with a 0-10 or 0-100 response.

  44. Patient Global Assessment of Health Status (PGA) [12 months]

    Patient global assessment (PGA) is one of the most widely used PROs in RA practice and research and is included in several composite scores such as the 28-joint Disease Activity Score (DAS28). PGA is often assessed by a single question with a 0-10 or 0-100 response.

  45. Patient Acceptable Symptom State (PASS) [Baseline]

    Patient Acceptable Symptom State (PASS) has been defined as the highest level of symptom beyond which patients consider themselves well.

  46. Patient Acceptable Symptom State (PASS) [2 months]

    Patient Acceptable Symptom State (PASS) has been defined as the highest level of symptom beyond which patients consider themselves well.

  47. Patient Acceptable Symptom State (PASS) [6 months]

    Patient Acceptable Symptom State (PASS) has been defined as the highest level of symptom beyond which patients consider themselves well.

  48. Patient Acceptable Symptom State (PASS) [12 months]

    Patient Acceptable Symptom State (PASS) has been defined as the highest level of symptom beyond which patients consider themselves well.

  49. Arthritis Self-Efficacy Questionnaire [Baseline]

    The ASES was developed to measure patients' arthritis-specific self-efficacy, or patients' beliefs that they could perform specific tasks or behaviors to cope with the consequences of arthritis.

  50. Arthritis Self-Efficacy Questionnaire [2 months]

    The ASES was developed to measure patients' arthritis-specific self-efficacy, or patients' beliefs that they could perform specific tasks or behaviors to cope with the consequences of arthritis.

  51. Arthritis Self-Efficacy Questionnaire [6 months]

    The ASES was developed to measure patients' arthritis-specific self-efficacy, or patients' beliefs that they could perform specific tasks or behaviors to cope with the consequences of arthritis.

  52. Arthritis Self-Efficacy Questionnaire [12 months]

    The ASES was developed to measure patients' arthritis-specific self-efficacy, or patients' beliefs that they could perform specific tasks or behaviors to cope with the consequences of arthritis.

  53. Center for the Epidemiological studies - Depression Scale (CES-D) [Baseline]

    The Center for Epidemiologic Studies Depression Scale is a commonly used freely available self-report measure of depressive symptoms.

  54. Center for the Epidemiological studies - Depression Scale (CES-D) [2 months]

    The Center for Epidemiologic Studies Depression Scale is a commonly used freely available self-report measure of depressive symptoms.

  55. Center for the Epidemiological studies - Depression Scale (CES-D) [6 months]

    The Center for Epidemiologic Studies Depression Scale is a commonly used freely available self-report measure of depressive symptoms.

  56. Center for the Epidemiological studies - Depression Scale (CES-D) [12 months]

    The Center for Epidemiologic Studies Depression Scale is a commonly used freely available self-report measure of depressive symptoms.

  57. Visual Analogue Scale to Evaluate Fatigue Severity (VAS-F) [Baseline]

    The scale consists of 18 items relating to the subjective experience of fatigue. Each item asks respondents to place an "X," representing how they currently feel, along a visual analogue line that extends between two extremes (e.g., from "not at all tired" to "extremely tired").

  58. Visual Analogue Scale to Evaluate Fatigue Severity (VAS-F) [2 months]

    The scale consists of 18 items relating to the subjective experience of fatigue. Each item asks respondents to place an "X," representing how they currently feel, along a visual analogue line that extends between two extremes (e.g., from "not at all tired" to "extremely tired").

  59. Visual Analogue Scale to Evaluate Fatigue Severity (VAS-F) [6 months]

    The scale consists of 18 items relating to the subjective experience of fatigue. Each item asks respondents to place an "X," representing how they currently feel, along a visual analogue line that extends between two extremes (e.g., from "not at all tired" to "extremely tired").

  60. Visual Analogue Scale to Evaluate Fatigue Severity (VAS-F) [12 months]

    The scale consists of 18 items relating to the subjective experience of fatigue. Each item asks respondents to place an "X," representing how they currently feel, along a visual analogue line that extends between two extremes (e.g., from "not at all tired" to "extremely tired").

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 74 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 40-74 years of age

  • Screened by the Southwest Musculoskeletal RAC as "mild to moderate OA" using clinical and radiographic criteria

Exclusion Criteria:
  • Concomitant end-stage OA (awaiting/prior TJA)

  • Inflammatory arthritis (rheumatoid, psoriatic, or disease-modifying anti-rheumatic drug exposure)

  • Unstable medical conditions that would preclude physical activity prescription (e.g. unstable angina, uncontrolled Type 2 Diabetes)

  • Not able/willing to follow up for the study period

  • Does not have access to the internet

  • Cannot communicate in English.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fowler Kennedy Sports Medicine Clinic London Ontario Canada N6A 3K7

Sponsors and Collaborators

  • Western University, Canada

Investigators

  • Principal Investigator: Jane Thornton, MD PhD, Western University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Western University, Canada
ClinicalTrials.gov Identifier:
NCT04544904
Other Study ID Numbers:
  • 2020TEAM
First Posted:
Sep 10, 2020
Last Update Posted:
Dec 10, 2021
Last Verified:
Aug 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Western University, Canada
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 10, 2021